Board of Directors Approved the Change of Financial Officer and Acting Spokesperson

IND Phase I/II Human Clinical Trial Application of Globo-H Antibody-Drug Conjugate, OBI-999, submission to FDA
August 3, 2019
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase I/II Study of its Antibody-Drug Conjugate (ADC) targeted cancer therapy, OBI-999
August 31, 2019
  1. Type of personnel changed (please enter: spokesperson, acting spokesperson, important perational officer, financial officer, accounting officer, company secretary, research and development officer, or internal audit officer): Financial officer and acting spokesperson
  2. Date of occurrence of the change: Aug 12, 2019
  3. Name, title, and resume of the replaced person: Not Applicable
  4. Name, title, and resume of the replacement:
    Financial Officer: Frank Chen, Board member and chief financial officer
    Acting Spokesperson: Ming-Tain Lai, R&D Executive Vice President
  5. Type of the change (please enter: “resignation”, “position adjustment”, “dismissal”, “retirement”, “death” or “new replacement” ): New replacement
  6. Reason for the change: New replacement
  7. Effective date: Aug 12, 2019
  8. Contact telephone number of the replacement: (02)2655-8799
  9. Any other matters that need to be specified: None